1.26

3.08% -0.04

After Hours: 1.29 0.03 +2.38%

Iterum Therapeutics Plc (ITRM)

Overview News Price History Financials Why ITRM Down? Discussions Forecast Stock Split

Iterum Therapeutics Plc stock is traded at $1.26, with a volume of 330.60K. It is down -3.08% in the last 24 hours and down -10.64% over the past month. Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Previous Close:

$1.30

Open:

$1.27

24h Volume:

330.60K

Relative Volume:

0.81

Market Cap:

$37.35M

Revenue:

Net Income/Loss:

$-35.58M

P/E Ratio:

-0.4755

EPS:

-2.65

Net Cash Flow:

$-42.82M

1W Performance:

+16.67%

1M Performance:

-10.64%

6M Performance:

-32.98%

1Y Performance:

-19.75%

1-Day Range:

$1.21

$1.31

1-Week Range:

$1.01

$1.42

52-Week Range:

$0.808

$3.02

Iterum Therapeutics Plc Stock (ITRM) Company Profile

Name

Iterum Therapeutics Plc

Sector

Healthcare (1176)

Industry

Biotechnology (677)

Phone

(872) 225-6077

Address

3 DUBLIN LANDINGS, DUBLIN 1

Employee

Twitter

Next Earnings Date

2025-02-07

Latest SEC Filings

ITRM's Discussions on Twitter

Compare ITRM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ITRM Iterum Therapeutics Plc	1.26	37.35M	0	-35.58M	-42.82M	-2.65
VRTX Vertex Pharmaceuticals Inc	493.84	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	602.64	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	614.76	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.56	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	244.90	24.70B	3.81B	-644.79M	-669.77M	-6.24

Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-28-21	Upgrade	Gabelli & Co	Sell → Hold
Mar-15-21	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-02-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jan-21-20	Downgrade	Gabelli & Co	Buy → Sell
Dec-11-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-21-19	Initiated	H.C. Wainwright	Buy

View All

Iterum Therapeutics Plc Stock (ITRM) Latest News

Apr 24, 2025

ITRM’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com

Apr 24, 2025

Iterum Therapeutics Plc (NASDAQ:ITRM) Shares Surged 24.11% In A Week – But Can It Maintain Its Gains? - Marketing Sentinel

Apr 24, 2025

Apr 14, 2025

Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics - The Manila Times

Apr 14, 2025

Groundbreaking Research Reveals Age-Specific Patterns in Antibiotic Resistance for UTI Patients - Stock Titan

Apr 14, 2025

Apr 07, 2025

What is Iterum Therapeutics Plc (ITRM) Stock Return on Shareholders’ Capital? - Sete News

Apr 07, 2025

Apr 05, 2025